Ionis and Roche report positive Phase 3 interim data for sefaxersen in IgA nephropathy
The IMAgINATION study hit its primary endpoint at 37 weeks, with the trial continuing blinded to assess kidney function through week 105.
SEC filing
Latest
9 stories
Tuesday, September 29
Wednesday, September 23
ProQR names Chris Hart as Chief Data and AI Officer, adds Thomas Wolf to board
The moves are meant to expand AI use across ProQR's Axiomer RNA editing programs, with an early readout for lead AI-discovered candidate AX-0811 expected in January 2027.
SEC filing
Friday, September 4
Novartis's pelacarsen fails cardiovascular outcomes trial in Phase 3 study
Lp(a)HORIZON did not reduce cardiovascular events despite lowering Lp(a) levels, Ionis and partner Novartis reported.
SEC filing
FDA approves Ionis's ZANVASTRO for Alexander disease
The agency cleared zilganersen as the first disease-modifying therapy for the ultra-rare neurological disorder and awarded Ionis a Rare Pediatric Disease Priority Review Voucher.
SEC filing
Thursday, September 3
FDA approval file confirms Zanvastro details for Alexander disease
Records show the approval letter and label were issued days after the FDA's September 3 clearance of Ionis Pharmaceuticals' zilganersen.
Drugs@FDA, FDA press release (2)
Monday, August 24
Ionis registers Phase 3 trial of obudanersen for Angelman syndrome due to UPD or imprinting defects
Wednesday, July 29
Ionis posts Q2 2026 results, flags second-half pipeline milestones
TRYNGOLZA and DAWNZERA launches build early momentum as Ionis awaits zilganersen approval, an Lp(a) outcomes readout, and a hepatitis B launch.
SEC filing